NovoCure
NVCR
262 hedge funds and large institutions have $5.83B invested in NovoCure in 2019 Q4 according to their latest regulatory filings, with 56 funds opening new positions, 82 increasing their positions, 80 reducing their positions, and 32 closing their positions.
75% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 32
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
19% more call options, than puts
Call options by funds: $65.1M | Put options by funds: $54.6M
17% more capital invested
Capital invested by funds: $4.99B → $5.83B (+$840M)
9% more funds holding
Funds holding: 240 → 262 (+22)
2.14% more ownership
Funds ownership: 68% → 70.14% (+2.1%)
3% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 80
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$89.5M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$69.6M |
| 3 |
Capital International Investors
Los Angeles,
California
|
+$59.3M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$32.1M |
| 5 |
DCP
Darsana Capital Partners
New York
|
+$28.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$52M |
| 2 |
Two Sigma Investments
New York
|
-$26.9M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$20.8M |
| 4 |
Mitsubishi UFJ Trust & Banking
Tokyo,
Japan
|
-$19.5M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$17.5M |
NVCR Hedge Fund Activity: Q4 2019 in Review
262 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q4 2019, worth a combined $5.83B — up 17% from $4.99B a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new NVCR positions and 32 closed out — a net gain of 24 holders — while 82 added to existing stakes and 80 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $89.5M. The largest seller was Baillie Gifford & Co, cutting an estimated $52M.
- 262 institutional investors held NovoCure (NVCR) as of Q4 2019, up from 240 in Q3 2019.
- Funds reported $5.83B of NovoCure stock for Q4 2019, up 17% quarter-over-quarter.
- 56 funds opened new NovoCure positions in Q4 2019 and 32 closed out, a net change of +24 holders.
- The largest NovoCure buyer in Q4 2019 was Morgan Stanley, an estimated $89.5M added.
- The largest NovoCure seller in Q4 2019 was Baillie Gifford & Co, an estimated $52M sold.
Based on aggregated 13F filings for Q4 2019.